[1]. Zhu, N., et al., A Novel Coronavirus from Patients with Pneumonia in China, 2019. New England Journal of Medicine, 2020. 382: 727-33.
[2]. WHO, WHO characterizes COVID-19 as a pandemic. 2020, World Health Organization: Geneva. 2019.
[3]. Chu, J., et al., Clinical characteristics of 54 medical staff with COVID-19: A retrospective study in a single center in Wuhan, China. J Med Virol, 2020. 92: 807-13.
[4]. Yu, F., et al., Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients. Clin Infect Dis, 2020.
[5]. Zhai, P., et al., The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents, 2020. 55: 105955.
[6]. Huang, X., et al., Epidemiology and Clinical Characteristics of COVID-19. Arch Iran Med, 2020. 23: 268-71.
[7]. Fadini, G.P., et al., Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest, 2020. 43: 867-69.
[8]. Chen, N., et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020. 395: 507-13.
[9]. Chan, J.F., et al., A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 2020. 395: 514-23.
[10]. Zhang, C., et al., Clinical and epidemiological characteristics of pediatric SARS-CoV-2 infections in China: A multicenter case series. PLoS Med, 2020. 17: e1003130.
[11]. Henry, B.M. and J. Vikse, Clinical Characteristics of Covid-19 in China. N Engl J Med, 2020. 382: 1860-61.
[12]. Zhu, N., et al., A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med, 2020. 382: 727-33.
[13]. Li, Z., et al., Active case finding with case management: the key to tackling the COVID-19 pandemic. Lancet, 2020. 396: 63-70.
[14]. Rothan, H.A. and S.N. Byrareddy, The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun, 2020. 109: 102433.
[15]. Adhikari, S.P., et al., Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty, 2020. 9: 29.
[16]. Kuiken, T., et al., Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet, 2003. 362: 263-70.
[17]. Wu, V.C., et al., Acute renal failure in SARS patients: more than rhabdomyolysis. Nephrol Dial Transplant, 2004. 19: 3180-82.
[18]. Kim, E.S., et al., Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19. J Korean Med Sci, 2020. 35: e142.
[19]. Feng, D., et al., Duration of symptom onset to hospital admission and admission to discharge or death in SARS in mainland China: a descriptive study. Trop Med Int Health, 2009. 14 Suppl 1: p. 28-35.
[20]. Oh, M.D., et al., Middle East respiratory syndrome: what we learned from the 2015 outbreak in the Republic of Korea. Korean J Intern Med, 2018. 33: 233-46.
[21]. Choi, W.S., et al., Clinical Presentation and Outcomes of Middle East Respiratory Syndrome in the Republic of Korea. Infect Chemother, 2016. 48: 118-26.
[22]. Huang, C., et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020. 395: 497-506.
[23]. Ke, W., et al., Epidemiological and clinical characteristics of 46 newly-admitted coronavirus disease 2019 cases in Beijing.In Chinese. Chin J Infect Dis, 2020. 38.
[24]. Chen, N., et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020. 395: 507-13.
[25]. Wong, C.K., et al., Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol, 2004. 136: 95-103.
[26]. Chen, T.T., et al., TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis. J Exp Med, 2005. 202: 955-65.
[27]. Yingtao, Z., et al., Clinical outcomes of COVID-19 cases and influencing factors in Guangdong province.In Chinese. Chin J Epidemiol, 2020. 41.
[28]. Wang, W., J. Tang and F. Wei, Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol, 2020. 92: 441-47.
[29]. McMichael, T.M., et al., COVID-19 in a Long-Term Care Facility - King County, Washington, February 27-March 9, 2020. MMWR Morb Mortal Wkly Rep, 2020. 69: 339-42.
[30]. Smetana, J., et al., Influenza vaccination in the elderly. Hum Vaccin Immunother, 2018. 14: 540-49.
[31]. Guo, Y.R., et al., The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res, 2020. 7: 11.
[32]. Xu, B., et al., Epidemiological data from the COVID-19 outbreak, real-time case information. Sci Data, 2020. 7: 106.
[33]. Xu, X.W.W.X., Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ (Clinical research ed.), 2020. m606.